Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwCLL 2019 | Clonal evolution and resistance mechanisms to BCL-2 receptor inhibition

Mary Ann Anderson • 20 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia

Mary Ann Anderson, MBBS, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, discusses the development of resistance to BCL-2 receptor inhibition, and what it means for treatment strategies. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Mary Ann Anderson

Important factors to consider when selecting between venetoclax & BTK inhibitors for CLL
2:32
Important factors to consider when selecting between venetoclax & BTK inhibitors for CLL
Mary Ann Anderson • 8 Sep 2023
VENICE II trial: health-related QoL in patients with CLL treated with venetoclax
0:49
VENICE II trial: health-related QoL in patients with CLL treated with venetoclax
Mary Ann Anderson • 8 Sep 2023
Novel BCL-2 & BCL-2/BCLxL inhibitors emerging for the treatment of hematological malignancies
2:30
Novel BCL-2 & BCL-2/BCLxL inhibitors emerging for the treatment of hematological malignancies
Mary Ann Anderson • 8 Sep 2023
iwCLL 2019 - facilitating the development of novel agents and treatment outcomes
0:59
iwCLL 2019 - facilitating the development of novel agents and treatment outcomes
Mary Ann Anderson • 21 Sep 2019

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Mary Ann Anderson • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Mary Ann Anderson • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Mary Ann Anderson • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Mary Ann Anderson • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals